Pro Feature
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moCompany
Biocon
India - Bangalore
POSACONAZOLE (posaconazole) by Biocon is 12. Approved for invasive aspergillus, such, those with hematologic malignancies with prolonged neutropenia from chemotherapy and 1 more indications. First approved in 2022.
Drug data last refreshed 20h ago
12.1 Mechanism of Action Posaconazole is an azole antifungal agent [see ] . 12.2 Pharmacodynamics Exposure Response Relationship Prophylaxis: In clinical studies of neutropenic patients who were receiving cytotoxic chemotherapy for acute myelogenous leukemia (AML) or myelodysplastic syndromes (MDS)…
Worked on POSACONAZOLE at Biocon? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Azole Antifungal
Posaconazole (MK-5592) Intravenous and Oral in Children (<2 Years) With Invasive Fungal Infection (MK-5592-127)
Pharmacokinetic of Posaconazole in Critically Ill Patients
Posaconazole (MK-5592) Intravenous and Oral in Children With Invasive Aspergillosis (IA) (MK-5592-104)
Posaconazole Prophylaxis for CAPA Prevention in Critically-Ill Patients
Posaconazole Pharmacokinetics in Patients Receiving Chemotherapy or Stem Cell Transplants
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/mo